Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Net Margin (2021 - 2025)

Lyra Therapeutics has reported Net Margin over the past 5 years, most recently at 99300.0% for Q4 2025.

  • Quarterly results put Net Margin at 99300.0% for Q4 2025, down 9404689.0% from a year ago — trailing twelve months through Dec 2025 was 7266.08% (down 117514.0% YoY), and the annual figure for FY2025 was 7266.08%, down 117514.0%.
  • Net Margin for Q4 2025 was 99300.0% at Lyra Therapeutics, down from 23936.0% in the prior quarter.
  • Over the last five years, Net Margin for LYRA hit a ceiling of 2545.09% in Q1 2022 and a floor of 129290.91% in Q4 2022.
  • Median Net Margin over the past 5 years was 4847.61% (2021), compared with a mean of 22160.46%.
  • Biggest five-year swings in Net Margin: crashed -12426619bps in 2022 and later skyrocketed 11891009bps in 2023.
  • Lyra Therapeutics' Net Margin stood at 5024.72% in 2021, then plummeted by -2473bps to 129290.91% in 2022, then surged by 92bps to 10380.82% in 2023, then surged by 49bps to 5253.11% in 2024, then tumbled by -1790bps to 99300.0% in 2025.
  • The last three reported values for Net Margin were 99300.0% (Q4 2025), 23936.0% (Q3 2025), and 4063.93% (Q2 2025) per Business Quant data.